Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study specifically aims to evaluate how well mocertatug rezetecan (Mo‐Rez) alone orin combination with bevacizumab works in treating ovarian cancer compared to bevacizumabalone or active observation (AO). The study also assesses whether Mo‐Rez is safe andtolerated well by participants in comparison to bevacizumab alone OR AO and will helpprovide a better understanding of the main side effects of the drugs.
Epistemonikos ID: f66dc295adc811c5ffeb64c4306479d4fab0b818
First added on: Jul 11, 2026